Clinical trials: Inflammatory Bowel Disease 1
Crohn's Disease
Study To Evaluate The Efficacy And Safety Of Oral PF-06651600 And PF-06700841 In Subjects With Moderate To Severe Crohn's Disease
The objectives of this study are to evaluate the efficacy, safety, tolerability, pharmacokinetics, and pharmacodynamics of PF-06651600 (200 mg for 8 weeks followed by 50 mg for 4 weeks) dosed once daily and PF-06700841 (60 mg for…
- Trial name
- NCT03395184
- Testing
- PF-06651600, PF-06700841
- Where
- 195 sites in United States, Australia and 24 more
- Volunteers
- 244 people
- Sponsor
- Pfizer
Autoimmune Diseases, Inflammatory Bowel Diseases
Chronic Inflammatory Disease, Lifestyle and Treatment Response
Chronic inflammatory diseases (CID) - including inflammatory bowel diseases (Crohn's disease and ulcerative colitis), rheumatic conditions (rheumatoid arthritis, axial spondyloarthritis, psoriatic arthritis), inflammatory skin…
- Conditions
- Autoimmune Diseases, Inflammatory Bowel Diseases, Crohn Disease (CD), Colitis, Ulcerative (UC)
- Trial name
- BELIEVE (NCT03173144)
- Testing
- Primary exposure variable, Other (exploratory) exposure variables
- Where
- 3 sites in Denmark
- Volunteers
- 233 people
- Sponsor
- University of Southern Denmark
Crohn's Disease, Ulcerative Colitis
Long-term Scheduled Therapy With Infliximab in Inflammatory Bowel Disease
The primary objective of this study is to evaluate sustained clinical remission (for the definition see below) in patients with inflammatory bowel disease receiving long-term (> 2 years) scheduled treatment with infliximab.
- Trial name
- NCT02057016
- Where
- Italy
- Volunteers
- 258 people
- Sponsor
- Catholic University of the Sacred Heart
Pouch, Ileal, Fistula
Study of Ossium Mesenchymal Stem Cells for the Treatment of Pouch Fistulas in the Setting of Crohn's Disease
The purpose of this study is to determine the safety and feasibility of using Ossium vertebral Bone Marrow Derived Mesenchymal Stem Cells (vBM-MSC) to treat people with an ileal pouch anal anastomosis (IPAA) who develop a fistula…
- Trial name
- NCT05075811
- Testing
- Ossium vBM-MSC
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Anthony Lembo
Inflammatory Bowel Diseases
Azathioprine Linked With Impaired Intestinal Epithelial Postoperative Regeneration in Crohn's Disease
What is known? the impact of AZA, immunomodulatory drug widely used in active CD, on the intestinal wall differs from those of steroids, what is reflected in the significant difference in the postoperative anastomotic leaks rate…
- Trial name
- NCT05456776
- Volunteers
- 35 people
- Sponsor
- Centre of Postgraduate Medical Education
Ulcerative Colitis, Crohn Disease
Impact of Additional Treatment With Saccharomyces Boulardii on Quality of Life in Patients With Mild Forms of Ulcerative Colitis and Crohn Disease
The goal of the study is to assess the impact of treatment with dietary supplement containing Saccharomyces boulardii (used as an addition to standard therapy), on quality of life of patients with mild forms of ulcerative colitis…
- Trial name
- NCT03941418
- Testing
- Boulardii
- Volunteers
- 150 people
- Sponsor
- University Clinic Dr Dragisa Misovic-Dedinje
Crohn's Disease
Efficacy and Safety of GLPG0634 in Subjects With Active Crohn's Disease
180 patients suffering from active Crohn's disease with evidence of mucosal ulceration will be evaluated for improvement of disease activity (efficacy) when taking GLPG0634 or matching placebo once daily for 20 weeks in addition…
- Trial name
- NCT02048618
- Testing
- GLPG0634
- Where
- 63 sites in Belgium, Czechia and 7 more
- Volunteers
- 175 people
- Sponsor
- Lakefront Biotherapeutics NV
Crohn's Disease
Examining the Long Term Safety, Efficacy, and Corticosteroid-sparing Effect of Certolizumab Pegol in Crohn's Disease
This is an open-label extension study designed to measure the safety, efficacy, and corticosteroid-sparing effect of certolizumab pegol (CDP870) in patients with moderate to severe Crohn's disease previously enrolled in C87059…
- Trial name
- COSPAR II (NCT00356408)
- Testing
- Certolizumab pegol
- Where
- 63 sites in United States, Canada and 1 more
- Volunteers
- 106 people
- Sponsor
- UCB Pharma
Crohn Disease
Efficacy of Vedolizumab in Crohn's Disease Patients Naive to Biological Therapy
INTRODUCTION: Vedolizumab is a gut selective anti-integrin agent which binds to the alfa4beta7 integrin, preventing its coupling to the endothelial MadCAM-1.
- Trial name
- NCT04362735
- Testing
- Vedolizumab
- Volunteers
- 100 people
- Sponsor
- Pontifícia Universidade Católica do Paraná
Inflammatory Bowel Diseases
Clinical Trial of TQH3906 Capsules for the Treatment of Adult Patients With Moderately to Severely Active Ulcerative Colitis or Crohn's Disease
This phase will commence following dose escalation in the 24mg bid group during Phase I. Employing a 1:1:1 randomized, double-blind, placebo-controlled study design, it will evaluate the efficacy, safety, and…
- Trial name
- NCT06754891
- Testing
- 24mg bid TQH3906 capsule, 32mg TQH3906 capsule
- Where
- 30 sites in China
- Volunteers
- 135 people
- Sponsor
- Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.
Moderately to Severely Active Crohns Disease
A Study to Assess the Efficacy and Safety of Induction and Maintenance Therapy With Afimkibart (RO7790121) in Participants With Moderately to Severely Active Crohn's Disease
This Phase III, multicenter, double-blind, placebo-controlled treat-through study will evaluate the efficacy and safety of induction and maintenance therapy with Afimkibart (also known as RO7790121) in participants with…
- Trial name
- SIBERITE-1 (NCT06819878)
- Testing
- Afimkibart
- Where
- 375 sites in United States, Argentina and 36 more
- Volunteers
- 600 people
- Sponsor
- Hoffmann-La Roche
Healthy
Study To Assess The Safety And Tolerability Of Increasing Single Doses Of ATR-107 (PF-05230900) In Healthy People
This is a "first in human" study to determine the safety and tolerability of the drug after single doses. Nine doses of increasing strength will be injected or infused (given into a vein) to 9 different groups of people.
- Trial name
- NCT01162889
- Testing
- ATR-107 (PF-05230900) SC Injection, ATR-107 (PF-05230900) IV Infusion
- Where
- 2 sites in United States
- Volunteers
- 70 people, healthy volunteers welcome
- Sponsor
- Pfizer
Inflammatory Bowel Diseases
Based on the Special Disease Management of Crohn's Disease Diet Studies
This project plans to develop a new diet therapy suitable for China -- CD-C-food, which is more in line with the common diet of Chinese patients' eating habits and economic conditions, and its expected therapeutic effect and…
- Trial name
- NCT04976491
- Testing
- CD-C-Food, EEN
- Where
- China
- Volunteers
- 5 people, healthy volunteers welcome
- Sponsor
- Second Affiliated Hospital, Zhejiang University, School of Medicine
Crohn's Disease
Risk Stratification of Rapid Disease Progression in Children With Crohn's Disease
The purpose of this study for children with a new diagnosis of Crohn's disease is to identify biomarkers found in the blood or stool to help predict which children are at risk of developing complications.
- Trial name
- RS (NCT00790543)
- Where
- 28 sites in United States, Canada
- Volunteers
- 1,813 people
- Sponsor
- Emory University
Inflammatory Bowel Diseases, Crohn Disease
Evaluation of Stricturing Crohn's Disease Using Digital Holographic Microscopy
Crohn's Disease (CD) patients, belonging to Inflammatory Bowel Disease (IBD), frequently suffer from uncontrolled intestinal inflammation. This can lead to severe disease complications requiring hospitalization.
- Trial name
- NCT03465215
- Testing
- Digital holographic microscopy
- Where
- Germany
- Volunteers
- 29 people
- Sponsor
- University Hospital Muenster
Crohn Disease
"Tasty&Healthy" Dietary Approach for Crohn's Disease
Despite the advent of multiple novel medications, many patients with Crohn's disease (CD) fail to achieve mucosal healing (MH). Exclusive enteral nutrition (EEN) has been shown to induce clinical remission accompanied by MH in…
- Trial name
- NCT04239248
- Testing
- Tasty&Healthy intervention group, EEN intervention group
- Where
- Israel
- Volunteers
- 129 people
- Sponsor
- Shaare Zedek Medical Center
Crohn's Disease
Study of Antibiotics in the Treatment of Colonic Crohn's Disease
Crohn's disease (CD) is a form of inflammatory bowel disease that can affect any part of the digestive system. Symptoms of this chronic illness include abdominal pain, bloating, nausea, vomiting, and diarrhea.
- Trial name
- NCT00257699
- Testing
- ciprofloxacin, metronidazole
- Where
- Canada
- Volunteers
- 12 people
- Sponsor
- Mount Sinai Hospital, Canada
Inflammatory Bowel Disease (Crohn's Disease and Ulcerative Colitis)
Spiritual Needs of European Patients With Inflammatory Bowel Disease and Their Caregivers
A European-wide cross-sectional non-interventional study, initiated by a pilot study in Italy, will be conducted. The first phase of the pilot study is a 6-step translation, adaptation, and validation of the extended version of…
- Trial name
- Spirit@IBD (NCT07020481)
- Volunteers
- 1,000 people
- Sponsor
- University of Padova
Crohn's Disease
A Study to Assess Adverse Events, Change in Disease Activity, and How Intravenous and Subcutaneous Risankizumab Moves Through the Body of Pediatric Participants With Moderately to Severely Active Crohn's Disease
Crohn's Disease (CD) is a gastrointestinal disease that can cause chronic diarrhea with or without gross bleeding, abdominal pain, weight loss, and fever.
- Trial name
- RISE (NCT05995353)
- Testing
- Risankizumab
- Where
- 85 sites in United States, Belgium and 19 more
- Volunteers
- 110 people
- Sponsor
- AbbVie
Crohn Disease
The ENIGMA Study: Eastern Inflammatory Bowel Disease Gut Microbiota
The incidence of inflammatory bowel diseases, (IBD) including Crohn's disease (CD) and ulcerative colitis (UC), is increasing in the developing world.
- Trial name
- NCT03462875
- Where
- Hong Kong
- Volunteers
- 532 people, healthy volunteers welcome
- Sponsor
- Chinese University of Hong Kong
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.